However, the impact of such pharmacokinetic changes on the individual degree of response to tamoxifen is less clear, and CYP2D6 genotyping alone has been not enough for predicting breast cancer outcomes in clinical settings (Abraham et al., 2010; Rae, 2011; Regan et al., 2012). The gene discussed is CYP2D6; the disease is breast cancer.